IN8bio

Focus: IN8bio is an oncology-focused biotechnology company developing autologous cell therapies combining cancer immunotherapy with chemotherapy approaches. The company operates as a pre-revenue biotech with a concentrated pipeline in solid and hematologic malignancies.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About IN8bio

AI assessmentNot Hiring

No open roles listed right now. Follow IN8bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EAGD T-cell infusion

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT03533816Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Phase 1

Help build intelligence for IN8bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage immuno-oncology platform with novel gamma-delta T cell approach offering meaningful differentiation in glioblastoma and AML
New York headquarters location provides access to top talent and proximity to major medical centers for clinical development
Pre-commercial stage enables opportunity to shape company strategy and build foundational infrastructure from the ground up

Watch Out For

No active hiring identified—zero open positions indicates potential resource constraints or development hiatus
Very early pipeline with only Phase 1/2 programs and no published data to validate approach; significant de-risking required

Generated by Claude from IN8bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Autologous genetically modified gamma-delta T cells

Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline